WO2005087249A1 - プロテアーゼ阻害剤及び疾患の予防又は治療剤 - Google Patents
プロテアーゼ阻害剤及び疾患の予防又は治療剤Info
- Publication number
- WO2005087249A1 WO2005087249A1 PCT/JP2005/004301 JP2005004301W WO2005087249A1 WO 2005087249 A1 WO2005087249 A1 WO 2005087249A1 JP 2005004301 W JP2005004301 W JP 2005004301W WO 2005087249 A1 WO2005087249 A1 WO 2005087249A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- protein
- gene encoding
- copd
- amino acid
- Prior art date
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title claims abstract description 29
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title claims abstract description 23
- 230000003449 preventive effect Effects 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 35
- 201000010099 disease Diseases 0.000 title abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 125
- 108090000171 Interleukin-18 Proteins 0.000 claims abstract description 82
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 80
- 102000003810 Interleukin-18 Human genes 0.000 claims abstract description 75
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 52
- 208000033065 inborn errors of immunity Diseases 0.000 claims abstract description 16
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims abstract description 16
- 235000018102 proteins Nutrition 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 37
- 239000003112 inhibitor Substances 0.000 claims description 35
- 229940124597 therapeutic agent Drugs 0.000 claims description 30
- 108091005804 Peptidases Proteins 0.000 claims description 27
- 239000004365 Protease Substances 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 26
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000003405 preventing effect Effects 0.000 claims description 9
- 230000000069 prophylactic effect Effects 0.000 claims description 9
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 6
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 6
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 206010001881 Alveolar proteinosis Diseases 0.000 abstract description 20
- 238000002560 therapeutic procedure Methods 0.000 abstract description 15
- 201000003489 pulmonary alveolar proteinosis Diseases 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 51
- 238000000034 method Methods 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 102000002933 Thioredoxin Human genes 0.000 description 31
- 108060008226 thioredoxin Proteins 0.000 description 31
- 229940094937 thioredoxin Drugs 0.000 description 29
- 238000010171 animal model Methods 0.000 description 28
- 102000035195 Peptidases Human genes 0.000 description 25
- 108090000426 Caspase-1 Proteins 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 235000019419 proteases Nutrition 0.000 description 18
- 102100035904 Caspase-1 Human genes 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 108010067372 Pancreatic elastase Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 102000016387 Pancreatic elastase Human genes 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 12
- 206010019280 Heart failures Diseases 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 206010014561 Emphysema Diseases 0.000 description 10
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 10
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000011532 immunohistochemical staining Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 206010019663 Hepatic failure Diseases 0.000 description 9
- 208000002815 pulmonary hypertension Diseases 0.000 description 9
- 208000007903 liver failure Diseases 0.000 description 8
- 231100000835 liver failure Toxicity 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000019693 Lung disease Diseases 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000044166 interleukin-18 binding protein Human genes 0.000 description 6
- 108010070145 interleukin-18 binding protein Proteins 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101100113615 Arabidopsis thaliana CITRX gene Proteins 0.000 description 5
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- 206010009192 Circulatory collapse Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 4
- 206010040560 shock Diseases 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 108090000203 Uteroglobin Proteins 0.000 description 3
- 102100031083 Uteroglobin Human genes 0.000 description 3
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101150103244 ACT1 gene Proteins 0.000 description 2
- 102000035101 Aspartic proteases Human genes 0.000 description 2
- 108091005502 Aspartic proteases Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000011814 C57BL/6N mouse Methods 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 101100161918 Glycine max SAC1 gene Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010014632 NF-kappa B kinase Proteins 0.000 description 2
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 2
- 206010039203 Road traffic accident Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 2
- 229940124446 critical care medicine Drugs 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical compound NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- QSUSKMBNZQHHPA-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-pyridin-4-ylimidazol-2-yl]but-3-yn-1-ol Chemical compound C=1C=CC=CC=1CCCN1C(C#CCCO)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=NC=C1 QSUSKMBNZQHHPA-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 229940124803 CXCR2 antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 description 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102000002149 Elafin Human genes 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000618525 Homo sapiens Membrane transport protein XK Proteins 0.000 description 1
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 1
- 101000954195 Homo sapiens Protein VAC14 homolog Proteins 0.000 description 1
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 1
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 1
- 108010049328 ICI 200355 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 101150053046 MYD88 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000960949 Mus musculus Interleukin-18 Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 101000894405 Mycobacterium leprae (strain TN) Bacterioferritin Proteins 0.000 description 1
- 108700023220 N-acetylneuraminate lyases Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241001313871 Puma Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 102000004002 Secretory Leukocyte Peptidase Inhibitor Human genes 0.000 description 1
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 1
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 description 1
- 102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 229950008654 butaprost Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 102000056461 human TXN Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 102000008625 interleukin-18 receptor activity proteins Human genes 0.000 description 1
- 108040002014 interleukin-18 receptor activity proteins Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- XRISENIKJUKIHD-LHQZMKCDSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,4r)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCC1([C@H](O)C\C=C\[C@@H]2[C@H](C(=O)C[C@H]2O)CCCCCCC(=O)OC)CCC1 XRISENIKJUKIHD-LHQZMKCDSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- YTXAYGAYACWVGD-UHFFFAOYSA-N palladium;hydrate Chemical compound O.[Pd] YTXAYGAYACWVGD-UHFFFAOYSA-N 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to an inhibitor of a protease considered to be one of the causes of chronic obstructive pulmonary disease, and an agent for preventing or treating chronic obstructive pulmonary disease, immunodeficiency syndrome, alveolar proteinosis, and cardiovascular disease. Things.
- COPD Chronic Obstructive Pulmonary Disease
- Non-patent document 1 Pauwels, R.A "Buist, AS, Calverley, PM, Jenkins, C.R” and Hurd, SS 'Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.NHLBI / WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. "American journal of respiratory and critical care medicinej, vol.163: PP.1256—1276, 2001.
- Non-Patent Document 2 Barnes, P.J. "Novel approaches and targets for treatment of chronic obstructive pulmonary disease.” American journal of respiratory and critical care medicinej, vol. 160: S72-79, 1999.
- Alveolar alveolar proteinosis is a disease of unknown cause that surfatatante protein and phospholipids accumulate in the alveoli.
- 90% of idiopathic cases show the presence of autoantibodies that suppress the activity of GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor).
- GM-CSF Gramulocyte-Macrophage Colony-Stimulating Factor
- Heart failure such as pulmonary heart caused by right heart load caused by chronic lung disease including COPD, and subsequent circulatory insufficiency such as liver failure and pulmonary hypertension, etc., cause the circulation related to COPD. It is known as organ disease.
- HIV human immunodeficiency virus
- CD4 a type of antigenic protein, a single-chain transmembrane d-glycoprotein with a molecular weight of 59 kDa
- cocktail therapy highly active antiretroviral therapy
- HAART therapy highly active antiretroviral therapy
- this cocktail therapy was not a radical treatment, it was reported that it not only increased immune cells in AIDS patients but also reduced the number of viruses in the blood to below the detection limit.
- elastase is known as a protease that hydrolyzes an insoluble protein elastin, which is a main component of elastic fibers constituting the lung. It has been long known that elastase induces emphysema, a type of COPD, when administered intratracheally, and elastase-administered animals have been used as animal models for emphysema.
- the present inventors came up with the possibility of using other IL-18 inhibitors as a therapeutic agent for COPD, and completed the present invention.
- the purpose of the present invention was to use proteases including elastase.
- proteases including elastase.
- a protease inhibitor which comprises at least one selected from the following (1) to (4):
- a protease is meta-mouth protease, serinbu mouth
- a chronic obstructive agent characterized by containing at least one protease inhibitor, [3] selected from the following (1) to (4), wherein the protease and cysteine protease are also selected.
- a prophylactic or therapeutic agent for pulmonary disease or immunodeficiency syndrome [4] preventing or treating chronic obstructive pulmonary disease, comprising at least one selected from the following (5) to (8): [5]
- a prophylactic or therapeutic agent for alveolar proteinosis comprising at least one selected from the following (5) to (8): [6]
- a protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence of an interleukin 18 inhibitor and having an interleukin 18 inhibitory activity (7) Gene encoding (1)
- the protease inhibitor containing the redox-active protein or its gene and the prophylactic or therapeutic agent for COPD of the present invention can strongly suppress COPD and can be used alone for the treatment of immunodeficiency syndrome groups. Or as a protease used in cocktail therapy such as HAART therapy. Since the redox-active protein or its gene is originally present in living cells, it has the advantage that it is conventionally used in cocktail therapy for immunodeficiency syndrome and has no side effects such as protease inhibitors. Have.
- the preventive or therapeutic agent for a disease containing an IL-18 inhibitor or a gene thereof according to the present invention is effective for treating cardiovascular diseases such as COPD, alveolar proteinosis, circulatory insufficiency associated with heart failure, hepatic insufficiency or pulmonary hypertension. Can be treated.
- FIG. 1 is a microscopic image of the lung tissue of the first group (control mice) of Example 2 (HE staining, X40 magnification)
- FIG. 2 is a microscopic image of lung tissue of the second group (pathological mouse model 1) of Example 2 (HE staining, X40 (f)
- FIG. 3 is a microscopic image of lung tissue of the third group (pathological mouse model 2) of Example 2 (HE staining, X40 (f)
- FIG. 4 is a microscopic image of lung tissue of the fourth group (etiology + therapeutic agent-administered mouse) of Example 2 (HE staining, X 40 ⁇ )
- FIG. 5 is a graph showing the mean alveolus length (mean linear intercept: Lm) of the mice in Groups 1 to 4 of Example 2.
- FIG. 6 is a microscopic image of lung tissue of a group (control) to which PBS was administered to the SPC-IL-18TG mouse of Example 3 (HE staining, ⁇ 40)
- FIG. 7 is a microscopic image of lung tissue of a group to which TRX was administered to the SPC-IL-18TG mouse of Example 3 (HE staining, X 40-fold).
- FIG. 8 Immunohistochemical staining showing the expression level of IL-18 in lung tissue of healthy human lung in Reference Example 1. It is a figure which shows the result of a color (immunostaining, X400 time).
- FIG. 9 is a view showing the results of immunohistochemical staining showing the expression level of IL-18 in lung tissue of a COPD patient in Reference Example 1 (immunohistochemical staining, ⁇ 40).
- FIG. 10 is a diagram showing the results of immunohistochemical staining showing the expression level of IL-18 in the lung tissue of a COPD patient in Reference Example 1 (immunohistological staining, ⁇ 200).
- FIG. 11 is a diagram showing the results of immunohistochemical staining showing the expression level of TRX in healthy human lung tissue in Reference Example 2 (immunohistological staining, ⁇ 40).
- FIG. 12 is a diagram showing the results of immunohistochemical staining showing the expression level of TRX in healthy human lung tissue in Reference Example 2 (immunohistological staining, X200-fold).
- FIG. 13 is a diagram showing the result of immunohistochemical staining showing the expression level of TRX in the lung tissue of a COPD patient in Reference Example 2 (immunohistological staining, ⁇ 40).
- FIG. 14 is a diagram showing the results of immunohistochemical staining showing the expression level of TRX in the lung tissue of a COPD patient in Reference Example 2 (immunohistological staining, X200-fold).
- FIG. 15 Sequence (DNA sequence) of mature IL-18 cDNA having a signal peptide.
- FIG. 16 is the recombinant gene SPC-IL-18SP used in the present invention.
- the protease is a protease that is a proteolytic enzyme.
- examples of the protease include meta-oral proteases, cysteine proteases, serine proteases, and aspartic proteases (acid proteases).
- the meta-mouth protease is a proteolytic enzyme having a heavy metal such as zinc as an active center, and examples thereof include matrix 'meta-mouth protease (hereinafter referred to as "MMP") ⁇ thermolysin and the like.
- MMP matrix 'meta-mouth protease
- MMPs are zinc-containing proteases that hydrolyze intercellular adhesive matrix proteins in animal cells and are involved in cell division, morphogenesis, and cancer metastasis. Nearly 30 types of MMPs, such as MMP-1, 2, ⁇ ⁇ ⁇ 28, have been identified.
- Cysteine protease is a protease having a cysteine residue as an active center, and examples thereof include caspase, ze, and papain.
- caspase 1 , 2, 3 ⁇ Nearly 20 types are among them.
- caspases 1, 3 and 9 are important as targets of the protease inhibitor of the present invention.
- Caspase which cleaves the C-terminal side of aspartic acid, exists as an inactive precursor and is cleaved by an apoptotic signal to become an active form.
- Specific examples include caspase 1 and the like, which is also called interleukin 1/3 converting enzyme and is known to cleave an IL-18 precursor to form an active form of IL-18.
- serine proteases include chymotrypsin, subtilisin, and the like in addition to elastase.
- Elastase is known as a protease that hydrolyzes insoluble protein elastin, which is a main component of elastic fibers constituting the lung.
- Aspartic proteases include pepsin and cathepsin D.
- the activity equivalent to the redox-active protein refers to a redox-regulating activity shown below.
- a redox-active protein is a protein capable of controlling redox (regulating the redox state) by having both redox activities (oxidation and reduction, reduction-oxidation). Quality, including redox-active peptides and the like.
- redox-active peptides and the like.
- polypeptides belonging to the thioredoxin family, HO-1 (hemoxygenase-1) and the like can be mentioned.
- Polypeptides belonging to the thioredoxin family refer to polypeptides belonging to the thioredoxin (hereinafter, referred to as "TRX") family (hereinafter, referred to as "TRX-P”) and dithiol bonds. And polypeptides having an acid-reducing activity of disulfide bonds, which are naturally present in biological cells (see Japanese Patent Application Laid-Open No. 2002-179588, etc.).
- TRX-P includes, in addition to polypeptides extracted from natural animals including humans, plants, Escherichia coli, and yeasts, polypeptides such as yeasts and Escherichia coli that are extracted by genetic recombination And polypeptides produced by chemical synthesis.
- polypeptides such as yeasts and Escherichia coli that are extracted by genetic recombination And polypeptides produced by chemical synthesis.
- those derived from humans, those produced by genetic recombination in Escherichia coli and yeast, and synthetic peptides consisting of the same or similar sequences to them are preferred because they are considered to have less influence on living organisms.
- TRXP has an active site containing a cysteine residue (one Cys XI—X2-Cys—: XI and X2 represent amino acid residues and may be the same or different). And a group of molecules with a similar three-dimensional structure. Therefore, in addition to the above, "TRX-P" referred to in the present invention includes those in which some amino acids are deleted or substituted within a range not impairing the dithiol bond or disulfide bond oxidation-reducing activity. And other amino acids and peptides may be fused.
- Specific examples of the active site include Cys—Gly—Pro—Cys—, Cys—Pro—Tyr—Cys —, — Cys—Pro—His—Cys—, Cys—Pro—Pro—Cys— and the like.
- Cys-Gly-Pro-Cys- is a sequence conserved across species, and is therefore preferable because the results of experiments using mouse models can be more reliably applied to humans.
- TRX P include thioredoxin (TRX), which is an active site mosquito Cys-Gly-Pro-Cys-, and daltaredoxin.
- TRX includes human, Escherichia coli, and yeast-derived TRX
- daltaredoxin includes human and Escherichia coli-derived.
- Examples of the active ingredient of the preventive or therapeutic agent for COPD, alveolar proteinosis, and circulatory disease of the present invention include the following (5) to (8) alone, and combinations thereof.
- a protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence of an interleukin 18 inhibitor and having an interleukin 18 inhibitory activity
- the IL-18 inhibitor of the present invention includes a substance that inhibits the conversion of IL-18 precursor to active IL-18, such as a cysteine protease inhibitor including an IL-1 ⁇ converting enzyme inhibitor. , IL-18 binding protein (IL-18 binding protein (IL-18BP) group, etc.) ⁇ Substances that neutralize the activity of IL-18, such as anti-IL-18 antibodies, recombinant type (The Combination of Soluble IL- 18R a and IL- 18R j8 Chains Inhioits IL-18- Induced IFN- ⁇ (Journal of Interferon and cytoine research 22: P.593-601, 2002, Mary and Liebert, Inc.)) or natural solubilized IL Substances that inhibit the binding of IL-18 to IL-18 receptor, such as -18 receptor (WO2005 / 12352), inhibitors of signal transduction after binding to IL-18 receptor, or genes encoding these No.
- IL-18 binding protein IL-18 binding protein (IL
- IL-1 ⁇ converting enzyme inhibitors Various compounds are known as IL-1 ⁇ converting enzyme inhibitors (ICE). Peptides similar to a site having affinity for ICE in the IL-1 ⁇ precursor include, for example, Aspl 16 force at the IL-1 ⁇ precursor cleavage site ⁇ 4 amino acid force toward the terminal side A peptide having the same peptide (TytVal-Ala-Asp) sequence is known to inhibit the binding of ICE to the IL_1 ⁇ precursor! / Puru (Japanese Patent Application Laid-Open No. 11-147895, [0002] See [Prior Art]). Further, as a specific example, for example, the peptide induction described in JP-A-5-255218 is disclosed.
- the IL-18 binding protein is a protein described in [Immunity, 10, 127-136 (1999)] and its subclasses, that is, a protein described at the end of P.136 of the reference.
- GenBank accession number means the IL-18 binding protein encoded by the gene represented by AF110798 or a subclass thereof.
- Examples of the subclass include proteins encoded by genes represented by GenBank accession numbers AF110799, AF110800, AF110801, AF110802, AF110803, AF110460, and the like described in the literature. These can be prepared according to the method described in the literature [Immunity, 10, 127-136 (1999)].
- a monoclonal antibody specific to IL-18 can be prepared according to the method described in the literature [J. Immunol. Methods, 217, 97-102 (1998)].
- Specific examples of the substance that inhibits the binding of IL-18 to the IL-18 receptor include, for example, a monoclonal antibody specific to the IL-18 receptor protein and the IL-18 receptor. I can do it.
- Monoclonal antibodies specific for the IL-18 receptor include Kitasato, Y., Hoshino, T., Okamoto, M., Kato, S., Koda, Y., Nagata, N., Kinoshita, M., Koga, H., Yoon, DY, Asao, H., Ohmoto, H., Koga, T., Rikimaru, T., and Aizawa, H.
- the monoclonal antibody specific to the IL-18 receptor may be an antibody derived from a mammal, a chimeric antibody or a humanized antibody.
- the monoclonal antibody specific to the IL-18 receptor protein and the IL-18 receptor used in the present invention can be prepared, for example, according to the method described in JP-A-11-100400. it can.
- IL lactate deacetylase
- RAF6 ⁇ receptor—associated Factor
- ⁇ - 1 TGF- ⁇ activated kinase
- MAPKK3,4,6 MAP kinase kinase
- JNK Jun
- N-terminal kinase N-terminal kinase
- p38 N-terminal kinase
- NIK NF- ⁇ B-inducing kinase
- IKK I ⁇ B-kinase
- Substances that inhibit IL-18 signal transduction molecules include, for example, p38 MAP kinase inhibitors SB203580, SB220025, RWJ 67657 (American Journal of Respiratory and
- the IL-18 inhibitor used in the present invention includes, in addition to the above-described IL-18 inhibitor itself, when the IL-18 inhibitor is a polypeptide, a gene encoding the polypeptide, Includes proteins with IL-18 inhibitory activity consisting of an amino acid sequence in which one or several amino acids have been deleted, substituted or added in the amino acid sequence of an IL-18 inhibitor, or a gene encoding these. It is.
- the active ingredients of the agent for preventing or treating COPD of the present invention include the above-mentioned substances ((1) to (4)) related to the redox-active protein and the substances related to the IL-18 inhibitor ((5 ) — (8)) can be used in combination.
- the content of the active ingredient in the protease inhibitor or the prophylactic or therapeutic agent for diseases of the present invention varies depending on the dosage form, and cannot be unconditionally limited. It may be selected appropriately in relation to the amount, for example, in the case of liquids, 0.0001-10 (w / v%), preferably ⁇ 0.001-5 (w / v%), especially in the case of injections , 0.0002-0.2 (w / v%), preferably 0.001-0.1 (w / v%), for solids, 0.01-50 (w / w%), preferably Is a force that can be adjusted to 0.02-20 (wZw%) or the like, but is not necessarily limited to this range.
- the dosage of the protease inhibitor or disease preventive or therapeutic agent of the present invention varies depending on the administration route, symptom, age, body weight, form of the preventive or therapeutic agent, and the like.
- the amount of the active ingredient in the prophylactic or therapeutic agent is 0.005 to 500 mg / kg, preferably 0.1 to 100 mg / kg body weight of the subject in need of treatment, provided that the Divide once or several times a day so that the lower limit is 0.1 Olmg (preferably 0.1 mg) and the upper limit is 20 g (preferably 200 mg, more preferably 500 mg, and still more preferably 100 mg) per day. It is desirable to administer according to the symptoms.
- the protease inhibitor and the agent for preventing or treating a disease of the present invention may be combined with a conventionally known component for preventing or treating a disease which is the object of the present invention.
- the preventive or therapeutic components include the following 1.5.
- LTB4 antagonists for example, LY29311, SC-53228, CP-105,696, SB201146, BIIL284
- o-Lipxygenase inhibitors for column? J or zileutin, Bayxl005
- hemokine inhibitors ⁇ IL-8 antagonists for example, SB225002; CXCR2 antagonists
- TNF inhibitors e.g., monoclonal Ab, soluble receptors, MMP inhibitors
- Antioxydants e.g., NAC, NAL, glutathione, superoxide dismutase, etc.
- Prostanoid inhibitors ⁇ row OX- 2 inhioitors, tnromboxane antagonists ⁇ isoprostane receptor
- Phosphodiesterase 4 inhibitors for example, SB207499, CP80633, CDP-840
- Adhesion inhibitors for example, anti-CD11 / CD18, anti- ICAM1, E-selectin inhibitors
- Prostaglandin E analogs for example, misoprostil, butaprost
- IL-10 Colchicine ⁇ Macrolide antibiotics
- Neutrophil elastase inhibitors for example, ICI200355, ONO-5046, MR-889, L658,758
- atnepsin inhioitors f row, j3 ⁇ 4 suramin
- Matrix metalioprotease innibitors f row for batimastat, marimastat, KBR7785
- alpha 1—antitrypsin f sequence is purified, human recomoinant, gene transfer
- Secretory leukoprotease inhibitor ⁇ Elafin etc.
- immunosuppressant FK506 For example, immunosuppressant FK506 etc.
- Agent for treating respiratory inflammatory disease or respiratory hypersensitivity Xanthine derivatives such as theophylline, ⁇ 2 receptor stimulants, anticholinergic agents, antiallergic agents, corticosteroids, and steroids such as inhaled steroids.
- the protease inhibitor or the preventive or therapeutic agent for diseases of the present invention may contain other components as long as the inhibitory effect, the preventive or therapeutic effect is not inhibited, and for example, pharmaceutically.
- Acceptable carriers include excipients, lubricants, binders, disintegrants, stabilizers, flavoring agents, diluents, surfactants, emulsifiers, solubilizers, absorption enhancers, humectants, adsorbents, It can be formulated by well-known methods using additives such as fillers, extenders, humectants, and preservatives.
- examples of the excipient include an organic excipient and an inorganic excipient.
- the protease inhibitor and the prophylactic or therapeutic agent for diseases of the present invention are mainly for oral administration, and specifically include, for example, tablets, capsules, granules, powders, pills, troches and the like. It is orally administered in the form of a syrup or a syrup.
- Examples of the administration form include oral administration, intravenous administration such as intravenous injection, intramuscular administration, transdermal administration, intradermal administration, subcutaneous administration, intraperitoneal administration, rectal administration, mucosal administration, and inhalation.
- intravenous administration such as intravenous injection is preferable in terms of safety and keeping blood concentration constant.
- the gene encoding the above-mentioned redox active protein can also be used as a protease inhibitor or a preventive or therapeutic agent for COPD or immunodeficiency syndrome in gene therapy.
- the IL-18 inhibitor is a polypeptide
- the gene encoding the IL-18 inhibitor may be used as a prophylactic or therapeutic agent for COPD, alveolar proteinosis, or cardiovascular disease in gene therapy.
- RNA in addition to DNA, RNA, a plasmid, a virus vector and the like can be used as the gene form, and it may be single-stranded or double-stranded.
- a method of directly administering an expression plasmid intramuscularly (DNA vaccine method), a ribosome method, a lipofectin method, a microinjection method, a calcium phosphate method
- viruses used for the virus vector include a DNA virus or an RNA virus such as a retrovirus, an adenovirus, an adeno-associated virus, a herpes virus, a vaccinia virus, a box virus, a poliovirus, and a simbis virus.
- a DNA virus or an RNA virus such as a retrovirus, an adenovirus, an adeno-associated virus, a herpes virus, a vaccinia virus, a box virus, a poliovirus, and a simbis virus.
- viruses retrovirus, adenovirus, adeno-associated virus, vaccinia virus, etc. are preferred, and adenovirus is particularly preferred.
- an appropriate administration route can be selected according to the disease, symptom and the like to be treated.
- the administration route includes, for example, vein, artery, subcutaneous, intradermal, intramuscular and the like.
- the preparation When administered by the “in vivo method”, for example, the preparation may be in the form of a liquid or the like. However, in general, the form of an injection or the like containing the gene as an active ingredient is necessary. If necessary, a conventional carrier may be added.
- ribosomes or membrane-fused ribosomes containing genes can be used in the form of ribosome preparations such as suspensions, freezers, and centrifugal concentrated freezers.
- HVJ Sendai virus
- Administering the protease inhibitor of the present invention or the agent for preventing or treating COPD or immunodeficiency syndrome, alveolar proteinosis, or circulatory disease in various forms as described above, or administering the protease inhibitor of the present invention or A gene that is a preventive or therapeutic agent for COPD, immunodeficiency syndrome, alveolar proteinosis, and cardiovascular disease can be prevented or treated by using gene therapy.
- the emphysema animal model used for confirming the COPD inhibitory effect can be a method described in the literature (Shapiro, SD Animal models for COPD. Chest, 117: 223S-227S, 2000). Specifically, for example, it can be prepared by intratracheally administering a pig elastase suspended in clean PBS using a syringe.
- a new COPD animal model developed by the present inventors can be used as a disease animal model used for confirming the COPD inhibitory effect.
- This animal model can be used as an animal model for alveolar proteinosis or cardiovascular disease in addition to COPD, but in the following description, it may be referred to as a COPD animal model for convenience. The manufacturing method is described below.
- the COPD animal model used herein is a recombinant gene characterized by containing any of the following genes (XI) to (Y2) under the control of a promoter that is expressed in a lung-specific manner. This is an animal model into which is introduced.
- (X2) a gene encoding a protein having the same amino acid sequence as that of interleukin 18, in which one or several amino acids in the amino acid sequence of interleukin 18 have been deleted, substituted or added.
- (Y2) a gene encoding a protein having the same amino acid sequence as that of caspase-1, which has an amino acid sequence in which one or several amino acids have been deleted, substituted or added in the amino acid sequence of caspase-1
- the recombinant gene to be introduced into this animal model may be the following (XI) or (X2) gene (hereinafter sometimes collectively referred to as “IL-18 genes”), or the following (Y1) or (Y2) It can be obtained by placing a gene (hereinafter sometimes referred to as “caspase 1 genes”) under the control of a promoter that is expressed in a lung-specific manner.
- a promoter that is specifically expressed in the lung include a promoter derived from a lung constituent cell, such as a lung surfatatatant promoter or a Clara cell promoter.
- (X2) a gene encoding a protein having an activity equivalent to that of IL-18, wherein the amino acid sequence of IL-18 has one or several amino acids deleted, substituted, or substituted, and the amino acid sequence has the same activity.
- (Y2) a gene encoding a protein having the same amino acid sequence as that of caspase-1, which has an amino acid sequence in which one or several amino acids have been deleted, substituted or added in the amino acid sequence of caspase-1
- the activity equivalent to IL-18 means signal transduction through an IL-18 receptor and the like, for example, an activity of inducing interferon ⁇ (IFN- ⁇ ) and the like.
- the activity equivalent to that of caspase 1 means the activity of cleaving the IL-18 precursor (pro-IL-18, proIL-18) to form the active form (mature IL-18, maturel-18). I do.
- lung surfatantant promoter human lung surfatantant promoter
- SPC promoter surfactant protein-C gene promoter.
- SPC promoter can be obtained, for example, according to the method described in Early restriction of peripheral and proximal cell lineages during formation of the lung.Proc Natl Acad Sci US A. 2002 Aug 6; 99 (16): 10482-7. it can.
- CC10 promoter examples include the CC10 promoter (sometimes referred to as CCSP).
- the CC10 promoter is, for example, cis-acting elements that confer lung epithelial cell expression of the CC10 gene.J Biol Chem. 1992 Jul 25; 267 (21): 14703-12.
- the disease animal model of the present invention can be efficiently created.
- a recombinant gene includes a signal peptide (SP) gene for promoting the release of a transgene to the outside of a cell, a sequence having an action of optimizing protein expression such as Kozak sequence, and an expressed gene. It is preferable to include a poly A sequence useful for fishing or the like.
- SP signal peptide
- a signal peptide is an amino acid sequence that helps a protein to pass through a cell membrane made of lipids due to its hydrophobicity when the protein is secreted outside the cell. After passing through the membrane, it is called a signal peptidase. It is cleaved by enzymes.
- Examples of the signal peptide include mouse immunoglobulin (hereinafter referred to as “Ig”) ⁇ chain ′ signal peptide and the like.
- Mouse Ig K chain 'signal peptide is described, for example, in Carroll, WL, E. Mendel, S. Levy. 1985.Hybndoma lusion cell lines contain an aberrant Kappa transcript. Ol. Immunol. 25: 991. .
- a Kozak sequence is a bacterial-derived DNA sequence rich in guanine-cytosine that was found around the ATG start codon of a gene, and has the effect of optimizing protein expression. This is the array used.
- the poly A sequence refers to a nucleotide sequence in a gene, in which adenylic acid (A) is continuously present.
- poly A sequence examples include a bovine poly A sequence and the like.
- a bovine poly A sequence For example, Goldman, LA, EC and utrone, SV Kotenko, and D. Krause, JA Langer. 1996. Modifications of vectors pEF—BOS, pcDNAl and pcDNA3 result in improved convenience and expression.BioTechniques 21: 1013. O.
- the recombinant gene is a gene using an IL-18 gene such as (XI) or (X2)
- a signal peptide is required to promote the release of the transgene to the outside of the cell.
- the IL-1 ⁇ converting enzyme (caspase-1) gene which converts proIL-18 to active IL-18, is introduced into an animal model together with IL-18 genes and expressed together. Other known techniques can also be used.
- the disease animal model can be created, for example, by the following method.
- the animals used in the present invention include rodents, dogs, cats, monkeys, pumas, pigs, and the like.
- rodents include mice, rats, and the like.
- a C57BL / 6N mouse also referred to as a # 6 mouse
- a Balb / c mouse or the like is preferably used as a mouse preferred by a force mouse
- a B6 mouse is particularly preferable.
- the case where the introduced animal is a mouse may be mainly described as an example, but the present invention is not limited to a mouse.
- a method for producing a recombinant gene including the above known methods for gene recombination can be used, and examples thereof are as follows.
- the power mainly explained by the IL-18 gene can be similarly applied to the IL-18-related gene (X2) and the caspase-1 genes (Yl) and (Y2). .
- the pro-IL-18 cDNA may be any of the above (X) or (Y) gene when it becomes active (mature IL-18).
- the sequence is exemplified in FIG. Figure 15 (Array 1)
- Array 1 The signal peptide gene derived from the V-J2-C region of the mouse Ig K chain from the sequence G at position 10 to the sequence C at position 69 immediately after the start codon "C.” From the AAC codon to the 3rd “AGT” immediately before the 541-543 “TAG” STOP codon is the mature mouse IL-18 cDNA.
- the "GGA ACA" before the start codon is a sequence region containing a Kozak sequence, which was originally present in the genome of mouse pro-IL-18 cDNA, and which optimizes protein expression.
- GTG after the STOP codon is a sequence originally present in the genome of mouse pro-IL-18 cDNA, but it is thought that it is not particularly necessary.
- the PCR product is cloned using the pCR2.1 vector (manufactured by Invitrogen) and sequenced (see references (1) and (2) above).
- the human surfatatatant promoter SPC (Early restriction of peripheral and proximal cell lineages during formation or the lung.Proc Natl Acad Sci US A. 2002 Aug 6; 99 (16): 10482-7.)
- SV40 small T intron (Early restriction of peripheral and proximal cell lineages during formation of the lung.Proc Natl Acad Sci US A.
- a known gene introduction method can be used as a method for introducing a recombinant gene into a mouse.
- the recombinant gene obtained as described above in a mouse fertilized egg (the above-described linear gene) can be used.
- DNA fragment) by microinjection injection time: pronuclear stage fertilized egg, Injection site: male pronucleus
- injection time pronuclear stage fertilized egg
- Injection site male pronucleus
- the recombinant gene injection can be confirmed by extracting DNA from tissues such as the tail of a born mouse (founder) using a DNAesay kit [Qiagen, Germany] and performing PCR. Mating with a male wild-type mouse (one that is not syngeneic to the surrogate mother), and selecting the offspring (either male or female, including F2, F3, '...) that express IL-18 By doing so, it is possible to produce recombinant gene introduction. Methods for selection include PCR analysis using genomic DNA from tissues such as the tail, ELISA analysis of mature IL-18 in serum, and Western blot analysis of mature IL-18 in lung, heart, liver, etc. (See the above references (1) and (2)).
- the amount of IL-18 gene under the control of a lung-specific promoter can be appropriately adjusted according to the type of mouse, the timing of onset, the degree of onset, and the like. Although not particularly limited, it is generally considered appropriate that the lung concentration of the mouse is 1 ng / lung or more (50 ng / kg body weight) and 10 ng / lung or less (500 ng / kg body weight).
- IL-18 it is preferable to introduce IL-18 in an animal model to such an extent that IL-18 expression becomes 1 ng / mL or more and lOng / mL or less in, for example, ELISA analysis of mature IL-18 in mouse serum.
- the larger the amount introduced the more the above-mentioned targeted lung diseases and cardiovascular diseases tend to develop.
- various diseases can develop at the same time.For example, since the lesions are different between lung disease and heart disease, it is possible to distinguish which site is effective in screening. . In addition, even when the disease site is the same disease, the characteristic disease states are different from each other, so that it is possible to determine which disease can be a drug candidate by analyzing individual organs.
- SPC-IL-18 introduction ability The time to onset is not particularly limited, but it begins to develop around 4 weeks of age as early as possible, almost starts around 5 weeks of age, and becomes stronger as the age increases Symptoms tend to appear. Early on, there is a difference in the type of disease that develops and its appearance, but around 5 to 8 weeks of age, most of the above lung and cardiovascular diseases tend to develop.
- the disease animal model obtained as described above includes lung diseases such as chronic obstructive pulmonary disease and alveolar proteinosis, and circulatory failure such as heart failure such as pulmonary heart, liver failure, and pulmonary hypertension.
- lung diseases such as chronic obstructive pulmonary disease and alveolar proteinosis
- circulatory failure such as heart failure such as pulmonary heart, liver failure, and pulmonary hypertension.
- heart failure such as pulmonary heart, liver failure, and pulmonary hypertension.
- Recombinant MMP-1 (Peptide Research Institute, Kyoto), Recombinant MMP-9 (Peptide Research Institute, Kyoto), using 50 M P3163-V (Peptide Research Institute, Kyoto) as substrate: MOCAc-Pro-Leu-Gly + Leu -Azpr (DNP) -Ala-Arg-NH2 was reacted at 37 ° C for 2 hours, and the amount of fluorescence was measured twice.
- TRX has an inhibitory effect on proteases such as cysteine protease and meta-mouth protease.
- Ovalbumin (OVA, SIGMA, 40 ⁇ g) suspended in 100 ⁇ L was intraperitoneally administered, and swine elastase (SIGMA Cat.No.E1250, 0.3U) suspended in 100 L of clean PBS was added.
- mice were collected on DAY21.
- Mouse lungs were perfused and fixed with 20% neutralized formalin at 15 cmH20 pressure from the bronchi.
- Lung paraffin sections were HE stained.
- Microscope images were captured by a digital camera for microscopes DXM1200 (manufactured by NIKON), and the analysis software was used by ACT-1 (manufactured by NIKON) and Photoshop (manufactured by Adobe). Specifically, each group randomly selects a lung tissue (slide). For both lungs of a single mouse, ACT-1 is used to capture images of 5 visual fields in each section from HE-stained slides of a total of 6 sections in the left, right, upper and middle lung fields.
- TRX which is a redox active protein, strongly and statistically significantly suppressed experimental pathological COPD using this system.
- mice Seven- to eight-week-old SPC-IL-18TG mice (5 mice per group), prepared as described above, are mixed with 0.1 mL of sterile phosphate buffer (PBS) (control) or 0.2 mL every other day. Dissolved recombinant human TRX 400 g / mL (ie, 40 g per animal) was administered intraperitoneally. Twenty-one days later, mouse lungs were collected and lung tissues were stained with HE.
- PBS sterile phosphate buffer
- TRX is known to have an inhibitory effect on IL-18, and by suppressing the IL-18 signal, TRX can prevent or treat the above-mentioned mouse models including COPD.
- the above-mentioned IL-18 inhibitors such as anti-IL-18 antibodies can also be used as therapeutic agents for cardiovascular diseases such as COPD, alveolar proteinosis, and circulatory insufficiency associated with heart failure, liver failure or pulmonary hypertension. Do you get it.
- Reference example 1
- Tissues obtained by surgery from 10 COPD patients and 6 lung tissues such as those who died in a traffic accident were fixed in formalin, and slices were prepared. Immunohistochemical staining was performed with an anti-human HL-18 antibody (cl one 8).
- Kitasato, Y. Hoshino, T., Okamoto, M., Kato, Koaa, Y., Nagata, N.,
- IL-18 was strongly expressed in the lung lesions of COPD patients. In particular, it was confirmed to be strongly expressed in infiltrating inflammatory cells and alveolar epithelium (Figs. 9 and 10).
- Paraffin sections were prepared by fixing formalin the tissues obtained from the surgery of 10 COPD patients and the lung tissues of six people, including those who died in traffic accidents. Immunohistological staining was performed with an anti-human TRX antibody (manufactured by Serotec). Immunohistochemical staining was performed according to the method described in the following article. Kitasato, Y., Hoshino, T., Okamoto, M., Kato, S., Koda, Y., Nagata, N., Kinoshita, M., Koga, H., Yoon, DY, Asao, H., Ohmoto , H., Koga, T., Rikimaru, T., and Aizawa, H. Enhanced expression of interleukin— 18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 31: 619—625, 2004.
- TRX was strongly expressed in the lung lesions of COPD patients. In particular, it was found to be strongly expressed in infiltrative cells, alveolar epithelium, and fibroblasts of the bronchi (Figs. 13, 14).
- Reference Examples 1 and 2 also support the possibility that the living body can express TRX to suppress IL-18 that is excessively expressed in COPD, and the above-mentioned IL-18 inhibitor Is also useful in the prevention or treatment of COPD.
- the prophylactic or therapeutic agent for COPD can be used alone or as a protease used in cocktail therapy such as HAART therapy for potently suppressing COPD and treating immunodeficiency syndrome.
- the preventive or therapeutic agent for a disease containing an IL-18 inhibitor or its gene of the present invention is effective against circulatory diseases such as circulatory insufficiency associated with COPD, alveolar proteinosis, heart failure, liver failure or pulmonary hypertension. Can be treated.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510996A JP4160615B2 (ja) | 2004-03-11 | 2005-03-11 | プロテアーゼ阻害剤 |
EP05720572A EP1736168A4 (en) | 2004-03-11 | 2005-03-11 | INHIBITOR OF PROSTHESIS AND PREVENTIVES OR REMEDIES FOR DISEASES. |
US11/825,646 US20080090766A1 (en) | 2004-03-11 | 2007-07-06 | Preventive or therapeutic agents for diseases including interleukin-18 inhibitor as an active ingredient |
US13/611,481 US20130072441A1 (en) | 2004-03-11 | 2012-09-12 | Protease Inhibitors and Preventives or Remedies for Disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004069835 | 2004-03-11 | ||
JP2004-069835 | 2004-03-11 | ||
JP2004-094065 | 2004-03-29 | ||
JP2004094065 | 2004-03-29 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10591843 A-371-Of-International | 2005-03-11 | ||
US11/825,646 Continuation US20080090766A1 (en) | 2004-03-11 | 2007-07-06 | Preventive or therapeutic agents for diseases including interleukin-18 inhibitor as an active ingredient |
US13/611,481 Division US20130072441A1 (en) | 2004-03-11 | 2012-09-12 | Protease Inhibitors and Preventives or Remedies for Disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005087249A1 true WO2005087249A1 (ja) | 2005-09-22 |
Family
ID=34975331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004301 WO2005087249A1 (ja) | 2004-03-11 | 2005-03-11 | プロテアーゼ阻害剤及び疾患の予防又は治療剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20130072441A1 (ja) |
EP (1) | EP1736168A4 (ja) |
JP (4) | JP4160615B2 (ja) |
WO (1) | WO2005087249A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007302633A (ja) * | 2006-05-12 | 2007-11-22 | Redox Bioscience Inc | 繊維質の燃焼時に発生する煙に含まれる有害成分によって引き起こされる障害の予防乃至治療剤 |
JP2012167121A (ja) * | 2005-02-25 | 2012-09-06 | Redox Bioscience Inc | 炎症性眼表面疾患の予防ないし治療剤 |
JP2018513116A (ja) * | 2015-03-05 | 2018-05-24 | エイビー2 バイオ ソシエテアノニム | 炎症性疾患におけるil−18結合タンパク質(il−18bp)および抗体 |
US10858426B2 (en) | 2013-09-05 | 2020-12-08 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) in inflammatory diseases |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100247538A1 (en) * | 2007-05-29 | 2010-09-30 | Yale University | IL-18 and Protein Kinase R Inhibition for the Treatment of COPD |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63230637A (ja) * | 1986-03-14 | 1988-09-27 | レプリゲン コ−ポレ−シヨン | 金属解媒による酸化被害の予防へのチオレドキシン化合物類の利用 |
JP2001510997A (ja) * | 1997-01-28 | 2001-08-07 | カロ バイオ アクチェブラーグ | 哺乳類チオレドキシン |
JP2005060408A (ja) * | 2004-11-30 | 2005-03-10 | Redox Bioscience Inc | 慢性閉塞性肺疾患の予防ないし治療剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780440A (en) * | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
US20020102654A1 (en) * | 1998-06-30 | 2002-08-01 | Incyte Pharmaceuticals, Inc | Thioredoxin proteins |
EP1231936A2 (en) * | 1999-10-27 | 2002-08-21 | K-Quay Enterprises, LLC | Methods and compositions for treatment of keratoconus using protease inhibitors |
GB0004531D0 (en) * | 2000-02-25 | 2000-04-19 | Richards Andrew J M | The treatment of respiratory diseases |
WO2002026803A2 (en) * | 2000-09-25 | 2002-04-04 | Millenium Pharmaceuticals, Inc. | 22108 and 47916, novel human thioredoxin family members and uses thereof |
JP2002179588A (ja) * | 2000-10-05 | 2002-06-26 | Jiyunji Yodoi | チオレドキシンファミリーに属するポリペプチド類を含む炎症予防乃至治療剤 |
AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
BR0116220A (pt) * | 2000-12-19 | 2003-09-23 | Sembiosys Genetics Inc | Métodos para a produção de proteìnas multiméricas e composições relacionadas |
AU2002323841B2 (en) * | 2001-06-05 | 2008-05-22 | Auckland Uniservices Limited | Methods and compositions for assessment of pulmonary function and disorders |
DE10132307A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
EP1356819A1 (en) * | 2002-04-25 | 2003-10-29 | Universitair Medisch Centrum Utrecht | Use of proteasome/ubiquitination inhibitors and/or MMP inhibitors alone or in combination with a growth hormone for treating /preventing catabolic conditions |
JP4651946B2 (ja) * | 2002-04-25 | 2011-03-16 | ザ スクリプス リサーチ インスティテュート | 肺病態の治療および予防 |
-
2005
- 2005-03-11 WO PCT/JP2005/004301 patent/WO2005087249A1/ja active Application Filing
- 2005-03-11 JP JP2006510996A patent/JP4160615B2/ja active Active
- 2005-03-11 EP EP05720572A patent/EP1736168A4/en not_active Withdrawn
-
2008
- 2008-04-04 JP JP2008098616A patent/JP4737648B2/ja active Active
-
2011
- 2011-03-25 JP JP2011068521A patent/JP4823389B2/ja active Active
- 2011-11-30 JP JP2011262938A patent/JP2012087136A/ja active Pending
-
2012
- 2012-09-12 US US13/611,481 patent/US20130072441A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63230637A (ja) * | 1986-03-14 | 1988-09-27 | レプリゲン コ−ポレ−シヨン | 金属解媒による酸化被害の予防へのチオレドキシン化合物類の利用 |
JP2001510997A (ja) * | 1997-01-28 | 2001-08-07 | カロ バイオ アクチェブラーグ | 哺乳類チオレドキシン |
JP2005060408A (ja) * | 2004-11-30 | 2005-03-10 | Redox Bioscience Inc | 慢性閉塞性肺疾患の予防ないし治療剤 |
Non-Patent Citations (6)
Title |
---|
FARINA A. ET AL: "Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion.", EUR J.BIOCHEM, vol. 268, no. 2, 2001, pages 405 - 13, XP002989523 * |
MACNEE W. ET AL: "Oxidants and antioxidants as therapeutic targets inc hronic obstructive pulmonary disease.", AM.J. RESPIR.CRIT.CARE MED, vol. 160, no. 2, 1999, pages S58 - 65, XP002989524 * |
POMERANTZ B. ET AL: "Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 an IL-1beta.", PROC NATL ACAD SCI U S A, vol. 98, no. 5, 2001, pages 2871 - 6, XP002217817 * |
See also references of EP1736168A4 * |
SEN C. ET AL: "Redox signaling and the emerging therapeutic potential of thiol antioxidants.", BIOCHEM PHARMACOL, vol. 55, no. 11, 1998, pages 1747 - 58, XP000900813 * |
UEDA S. ET AL: "Redox regulation of caspase-3 (-like) protease activity: regulatory roles of theioredoxin and cytochrome c.", J IMMUNOL, vol. 161, no. 12, 1998, pages 6689 - 95, XP002989522 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012167121A (ja) * | 2005-02-25 | 2012-09-06 | Redox Bioscience Inc | 炎症性眼表面疾患の予防ないし治療剤 |
JP2007302633A (ja) * | 2006-05-12 | 2007-11-22 | Redox Bioscience Inc | 繊維質の燃焼時に発生する煙に含まれる有害成分によって引き起こされる障害の予防乃至治療剤 |
US10858426B2 (en) | 2013-09-05 | 2020-12-08 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) in inflammatory diseases |
JP2018513116A (ja) * | 2015-03-05 | 2018-05-24 | エイビー2 バイオ ソシエテアノニム | 炎症性疾患におけるil−18結合タンパク質(il−18bp)および抗体 |
US10882905B2 (en) | 2015-03-05 | 2021-01-05 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
JP2021176860A (ja) * | 2015-03-05 | 2021-11-11 | エイビー2 バイオ ソシエテアノニム | 炎症性疾患におけるil−18結合タンパク質(il−18bp)および抗体 |
JP7274259B2 (ja) | 2015-03-05 | 2023-05-16 | エイビー2 バイオ ソシエテアノニム | 炎症性疾患におけるil-18結合タンパク質(il-18bp)および抗体 |
US11820817B2 (en) | 2015-03-05 | 2023-11-21 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
US11926663B2 (en) | 2015-03-05 | 2024-03-12 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
JP4160615B2 (ja) | 2008-10-01 |
JP4823389B2 (ja) | 2011-11-24 |
EP1736168A1 (en) | 2006-12-27 |
US20130072441A1 (en) | 2013-03-21 |
JP2012087136A (ja) | 2012-05-10 |
JP2011140511A (ja) | 2011-07-21 |
JP4737648B2 (ja) | 2011-08-03 |
JPWO2005087249A1 (ja) | 2008-01-24 |
JP2008201790A (ja) | 2008-09-04 |
EP1736168A4 (en) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10434134B2 (en) | Peptide treatment for inflammation and fibrosis | |
JP4823389B2 (ja) | 慢性閉塞性肺疾患の治療剤又は予防剤 | |
EP2892920B1 (en) | Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof | |
US20040072754A1 (en) | Amyloid precursor protein and APP-deprived peptides inhibit tumor growth and metastasis | |
MX2014007799A (es) | Peptidos y metodos para usarlos. | |
SK130696A3 (en) | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors | |
US8771700B2 (en) | Interferon antagonists, antibodies thereto and associated methods of use | |
AU2002352119B2 (en) | Human cDNAs and proteins and uses thereof | |
US20080090766A1 (en) | Preventive or therapeutic agents for diseases including interleukin-18 inhibitor as an active ingredient | |
JP2009509979A (ja) | グランザイムb阻害のための組成物および方法 | |
AU714536B2 (en) | Novel gene up-regulated in regenerating liver | |
JP4961559B2 (ja) | インターロイキン18阻害剤を有効成分とする疾患の予防又は治療剤 | |
JP2003300906A (ja) | がん転移抑制因子の安定化 | |
EP1568376B1 (en) | Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds | |
US11492390B2 (en) | Mutant alpha-1-antitrypsin compositions and use thereof | |
US20200282031A1 (en) | Methods and compositions for reducing lung injury associated with lung transplantation | |
WO2005087925A1 (ja) | 組換遺伝子,疾患動物モデル,及び被験物の評価方法 | |
EP1651254A1 (en) | Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1-antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds | |
JP5121400B2 (ja) | 筋ジストロフィ治療薬 | |
JP2007262027A (ja) | At−iiiによる内因性igf−1の産生誘導剤 | |
JPWO2004016784A1 (ja) | プロテアーゼ阻害剤 | |
McCarthy et al. | Antiproteases as Therapeutics to Target Inflammation in Chronic Obstructive Pulmonary Disease | |
JP2007297279A (ja) | ダニグループ1アレルゲンの改変体 | |
JPWO2003096804A1 (ja) | ヘパリン結合性上皮増殖因子様増殖因子遺伝子機能改変動物、スクリーニング方法、胚性幹細胞、並びに心不全予防および/または治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510996 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005720572 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005720572 Country of ref document: EP |